Energy Select Sector SPDR Fund (XLE) Stock Price Today
Aura AI Summary
Key Stats
- -Market Cap
- -Volume
- -Sector
- $62.5752W High
- $42.1252W Low
- -Typical Hold Time
- -Enterprise Value
- -Div Yield
- -Trading Activity
Track Energy Select Sector SPDR Fund (XLE) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Energy Select Sector SPDR Fund has traded between a low of $42.12 and a high of $62.57, highlighting its annual price range. Buy and sell Energy Select Sector SPDR Fund shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Most Recent News
US Department of War suspends costly CMMC Phase II cybersecurity rules for small defense contractors.
The U.S. Department of War has suspended the Cybersecurity Maturity Model Certification (CMMC) Phase II requirements originally set for November 2026, following concerns from small defense contractors about high compliance costs and bureaucratic burd...
AI use in cybersecurity jumps to 78% in 2026, but governance and failures lag behind.
The 2026 SANS AI Survey reveals rapid AI adoption in cybersecurity, with 78% of organizations using AI, up from 50% last year. However, governance structures and formal audit frameworks have not kept pace, leading to increased AI-related failures in ...
Head and neck squamous cell carcinoma market to grow 10.5% CAGR through 2036 with new immunotherapies.
The head and neck squamous cell carcinoma (HNSCC) market is projected to grow at a 10.5% CAGR from 2026 to 2036, driven by rising cancer incidence and new immunotherapy launches. Key emerging therapies from companies like Johnson & Johnson, BioNTech,...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.